IL273920B2 - Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[3,1]dioxolo[5,4-f]indol-7-yl)pyrrole-5,2-dione - Google Patents

Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[3,1]dioxolo[5,4-f]indol-7-yl)pyrrole-5,2-dione

Info

Publication number
IL273920B2
IL273920B2 IL273920A IL27392020A IL273920B2 IL 273920 B2 IL273920 B2 IL 273920B2 IL 273920 A IL273920 A IL 273920A IL 27392020 A IL27392020 A IL 27392020A IL 273920 B2 IL273920 B2 IL 273920B2
Authority
IL
Israel
Prior art keywords
solid form
methyl
fluorobenzofuran
dioxolo
indol
Prior art date
Application number
IL273920A
Other languages
English (en)
Hebrew (he)
Other versions
IL273920B1 (en
IL273920A (en
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of IL273920A publication Critical patent/IL273920A/en
Publication of IL273920B1 publication Critical patent/IL273920B1/en
Publication of IL273920B2 publication Critical patent/IL273920B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL273920A 2017-10-16 2018-10-16 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[3,1]dioxolo[5,4-f]indol-7-yl)pyrrole-5,2-dione IL273920B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (3)

Publication Number Publication Date
IL273920A IL273920A (en) 2020-05-31
IL273920B1 IL273920B1 (en) 2025-03-01
IL273920B2 true IL273920B2 (en) 2025-07-01

Family

ID=64110166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273920A IL273920B2 (en) 2017-10-16 2018-10-16 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[3,1]dioxolo[5,4-f]indol-7-yl)pyrrole-5,2-dione

Country Status (16)

Country Link
US (3) US11407759B2 (enExample)
EP (2) EP4740944A3 (enExample)
JP (2) JP7776258B2 (enExample)
KR (1) KR102891811B1 (enExample)
CN (1) CN111315748B (enExample)
AU (1) AU2018352384B2 (enExample)
CA (1) CA3074037A1 (enExample)
DK (1) DK3697794T3 (enExample)
ES (1) ES3064009T3 (enExample)
FI (1) FI3697794T3 (enExample)
IL (1) IL273920B2 (enExample)
MX (1) MX2020003431A (enExample)
PL (1) PL3697794T3 (enExample)
PT (1) PT3697794T (enExample)
WO (1) WO2019079299A1 (enExample)
ZA (1) ZA202002740B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
WO2019032958A1 (en) * 2017-08-11 2019-02-14 Actuate Therapeutics Inc. SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
WO2019032958A1 (en) * 2017-08-11 2019-02-14 Actuate Therapeutics Inc. SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRITTAIN, HARRY G., POLYMORPHISM IN PHARMACEUTICAL SOLIDS, 31 December 2009 (2009-12-31) *
IRINA N. GAISINA ET AL,, FROM A NATURAL PRODUCT LEAD TO THE IDENTIFICATION OF POTENT AND SELECTIVE BENZOFURAN-3-YL-(INDOL-3-YL)MALEIMIDES AS GLYCOGEN SYNTHASE KINASE 3[BETA] INHIBITORS THAT SUPPRESS PROLIFERATION AND SURVIVAL OF PANCREATIC CANCER CELLS, 31 December 2009 (2009-12-31) *
K. PAL ET AL,, INHIBITION OF GSK-3 INDUCES DIFFERENTIATION AND IMPAIRED GLUCOSE METABOLISM IN RENAL CANCER, 31 December 2013 (2013-12-31) *

Also Published As

Publication number Publication date
JP2024001040A (ja) 2024-01-09
ES3064009T3 (en) 2026-04-22
ZA202002740B (en) 2025-12-17
KR20200100615A (ko) 2020-08-26
AU2018352384B2 (en) 2023-12-21
AU2018352384A1 (en) 2020-05-21
US20200239489A1 (en) 2020-07-30
PT3697794T (pt) 2026-03-04
JP2020536944A (ja) 2020-12-17
JP7776258B2 (ja) 2025-11-26
WO2019079299A1 (en) 2019-04-25
CN111315748A (zh) 2020-06-19
IL273920B1 (en) 2025-03-01
FI3697794T3 (fi) 2026-02-10
CA3074037A1 (en) 2019-04-25
DK3697794T3 (da) 2026-02-02
MX2020003431A (es) 2020-07-29
US11407759B2 (en) 2022-08-09
EP3697794A1 (en) 2020-08-26
BR112020007538A2 (pt) 2020-09-24
US20250115615A1 (en) 2025-04-10
US20220348591A1 (en) 2022-11-03
EP4740944A2 (en) 2026-05-13
IL273920A (en) 2020-05-31
EP4740944A3 (en) 2026-07-29
CN111315748B (zh) 2023-06-27
US12116374B2 (en) 2024-10-15
EP3697794B1 (en) 2025-12-24
PL3697794T3 (pl) 2026-04-07
KR102891811B1 (ko) 2025-11-28

Similar Documents

Publication Publication Date Title
FI3978483T3 (fi) (S)-afoksolaneerin kiteinen tolueenisolvaatti
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013237682A5 (enExample)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2013543867A5 (enExample)
RU2015100280A (ru) Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи
JP2016028085A5 (enExample)
JP2016528179A5 (enExample)
RU2018101363A (ru) Кристаллическая форма свободного основания лорлатиниба
RU2017142958A (ru) Кристаллы азабициклического соединения
IL273920B1 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP2015522037A5 (enExample)
CN106748818B (zh) 重酒石酸间羟胺的合成方法
JP2016503752A5 (enExample)
JP2011515421A5 (enExample)
CN104316608B (zh) 阿齐沙坦酯杂质的检测及其制备方法
Zhang et al. Melohemsines AI, melodinus-type alkaloids from Melodinus hemsleyanus
FI3317264T3 (fi) (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola
HRP20210667T1 (hr) Kristalni oblici antagonista androgenog receptora, postupak pripreme i njihova upotreba
FI3665176T3 (fi) 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja
JP2017535510A5 (enExample)
RU2019133577A (ru) ТВЕРДАЯ ФОРМА (S)-[2-хлор-4-фтор-5-(7-морфолин-4-илхиназолин-4-ил)фенил]-(6-метокси-пиридазин-3-ил)метанола
JP2024001040A5 (enExample)
WO2013124748A4 (en) Novel polymorphs of azilsartan medoxomil potassium
AU2021347913A1 (en) Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same